{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:16:20Z","timestamp":1788498980175,"version":"build-2803163510"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Alveolar soft part sarcoma (ASPS) is a rare soft tissue sarcoma with high metastatic potential and limited response to systemic therapy. Biomarkers that predict which patients may benefit from emerging immune checkpoint inhibitors (ICIs) continue to surface. We report a case of stage IV ASPS with extensive pulmonary metastases and high PD-L1 expression that exhibited a marked response to atezolizumab, a PD-L1 antagonist. A 35-year-old man presented to an outside institution in October 2023 with a painless, progressively enlarging left thigh mass. Magnetic resonance imaging (MRI) demonstrated a 7.5 \u00d7 4.5 \u00d7 14\u00a0cm heterogeneous intramuscular lesion. Chest computed tomography (CT) revealed innumerable bilateral pulmonary metastases. Transthoracic biopsy of a pulmonary nodule confirmed stage IV ASPS with strong nuclear TFE3 positivity, Cathepsin K positivity, retained INI1 expression, and PD-L1 expression in 90-100% of malignant cells. The primary lesion was not characterized separately. Following transfer to our institution, atezolizumab was initiated in December 2023. At 3 months, chest CT demonstrated a marked regression of pulmonary metastases. Many resolved completely while others showed significant interval decrease in size. At 8 months, chest CT demonstrated further regression in size, number, and density of the pulmonary metastases. Only micronodules remained. At 12 months, chest CT demonstrated that all remaining pulmonary micronodules were stable without new or progressive disease. The primary lesion was treated with neoadjuvant hypofractionated radiotherapy and wide local resection. Post-operative histopathology of the primary lesion demonstrated &amp;gt;99% tumor necrosis with negative margins. This patient achieved a partial response of the primary thigh mass per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and an immune partial response per immune RECIST (iRECIST). Moreover, this patient experienced a near-complete resolution of pulmonary metastatic disease sustained for 27 months despite an extensive metastatic burden. This case illustrates that substantial disease burden does not preclude meaningful, durable response to ICIs. Moreover, it raises the possibility that high PD-L1 expression may contribute to immune evasion. However, this observation was based on a metastatic biopsy. Prospective acquisition of standardized PD-L1 assay data, fusion-variant genotyping, and tumor-infiltrating lymphocyte profiles in future cases could inform individualized prognostication.<\/jats:p>","DOI":"10.3389\/fonc.2026.1871862","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:27:01Z","timestamp":1788496021000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A partial response to atezolizumab in alveolar soft part sarcoma with near-complete resolution of extensive pulmonary metastases: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Joshua Ron","family":"Onichino","sequence":"first","affiliation":[{"name":"Faculty of Medicine and Health Sciences, McGill University","place":["Montreal, QC, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dev","family":"Patel","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences, McGill University","place":["Montreal, QC, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Powell","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences, McGill University","place":["Montreal, QC, Canada"]},{"name":"Department of Diagnostic Radiology, McGill University Health Center","place":["Montreal, QC, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Man Git","family":"Tsui","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences, McGill University","place":["Montreal, QC, Canada"]},{"name":"Department of Oncology, Division of Radiation Oncology, McGill University Health Center","place":["Montreal, QC, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramy","family":"Saleh","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences, McGill University","place":["Montreal, QC, Canada"]},{"name":"Department of Oncology, McGill University Health Center","place":["Montreal, QC, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Bozzo","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences, McGill University","place":["Montreal, QC, Canada"]},{"name":"Department of Orthopedic Surgery, McGill University Health Center","place":["Montreal, QC, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33618","article-title":"Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities","volume":"127","author":"Stacchiotti","year":"2021","journal-title":"Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010201)91:3<585::AID-CNCR1038>3.0.CO;2-0","article-title":"Alveolar soft part sarcoma","volume":"91","author":"Portera","year":"2001","journal-title":"Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyad102","article-title":"Advances in treatment of alveolar soft part sarcoma: An updated review","volume":"53","author":"Fujiwara","year":"2023","journal-title":"Jpn J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000026805","article-title":"The current management of alveolar soft part sarcomas","volume":"100","author":"Chang","year":"2021","journal-title":"Medicine"},{"key":"B5","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/sj.onc.1204074","article-title":"The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25","volume":"20","author":"Ladanyi","year":"2001","journal-title":"Oncogene"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-23-2115","article-title":"ASPSCR1::TFE3 drives alveolar soft part sarcoma by inducing targetable transcriptional programs","volume":"84","author":"Sicinska","year":"2024","journal-title":"Cancer Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.70305","article-title":"Complete response to nivolumab and ipilimumab after pazopanib discontinuation in a seven-year-old girl with alveolar soft part sarcoma: A case report and literature review","volume":"8","author":"Eghbali","year":"2025","journal-title":"Cancer Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.4490","article-title":"Diagnosis, prognosis, and treatment of alveolar soft-part sarcoma: A review","volume":"5","author":"Paoluzzi","year":"2019","journal-title":"JAMA Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmorc.2025.100002","article-title":"Advances in alveolar soft part sarcoma treatment in the era of immunotherapy","volume":"1","author":"Suto","year":"2025","journal-title":"ESMO Rare Cancers"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: Guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1186\/s12885-022-09968-5","article-title":"Alveolar soft part sarcoma: Progress toward improvement in survival? A population-based study","volume":"22","author":"Fujiwara","year":"2022","journal-title":"BMC Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303383","article-title":"Atezolizumab for advanced alveolar soft part sarcoma","volume":"389","author":"Chen","year":"2023","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.116104","article-title":"Clinical, immunological, and genomic findings of atezolizumab in advanced alveolar soft part sarcoma: A phase II trial (ALBERT trial\/NCCH1907)","volume":"232","author":"Kojima","year":"2026","journal-title":"Eur J Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.02.007","article-title":"Gamma Knife radiosurgery as a therapeutic strategy for intracranial sarcomatous metastases","volume":"76","author":"Flannery","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1249093","article-title":"Necrosis of a skin autograft after short-term treatment with sunitinib in a 14-year-old girl with metastatic alveolar soft part sarcoma of the thigh","volume":"222","author":"Hanzer","year":"2010","journal-title":"Klin Padiatr"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/jso.24183","article-title":"Prognostic factors in alveolar soft part sarcoma: A SEER analysis","volume":"113","author":"Wang","year":"2016","journal-title":"J Surg Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2020.06.007","article-title":"Characterization of alveolar soft part sarcoma using a large national database","volume":"168","author":"Hagerty","year":"2020","journal-title":"Surgery"},{"key":"B19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/labinvest.2017.128","article-title":"Immune checkpoint inhibitors in sarcomas: In quest of predictive biomarkers","volume":"98","author":"Veenstra","year":"2018","journal-title":"Lab Invest"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JGO.2017.009993","article-title":"Positive tumor response to combined checkpoint inhibitors in a patient with refractory alveolar soft part sarcoma: A case report","author":"Conley","year":"2017","journal-title":"JGO"},{"key":"B21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032713-120257","article-title":"TGF-\u03b2 activation and function in immunity","volume":"32","author":"Travis","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-02811","article-title":"Atezolizumab for alveolar soft part sarcoma: A clinical trial update","volume":"44","author":"Chen","year":"2026","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00385","article-title":"CTLA-4 and PD-1 pathway blockade: Combinations in the clinic","volume":"4","author":"Callahan","year":"2015","journal-title":"Front Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12040764","article-title":"Immunological mechanisms behind anti-PD-1\/PD-L1 immune checkpoint blockade: Intratumoral reinvigoration or systemic induction","volume":"12","author":"Guo","year":"2024","journal-title":"Biomedicines"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.05.013","article-title":"PD-L1 immunohistochemistry comparability study in real-life clinical samples: Results of blueprint phase 2 project","volume":"13","author":"Tsao","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0082870","article-title":"Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas","volume":"8","author":"Kim","year":"2013","journal-title":"PLoS One"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2014.11.001","article-title":"Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment","volume":"46","author":"D\u2019Angelo","year":"2015","journal-title":"Hum Pathol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1186\/s12885-016-2451-6","article-title":"Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma","volume":"16","author":"Kim","year":"2016","journal-title":"BMC Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_432234","article-title":"Immunotherapy in sarcoma: Current data and promising strategies","volume":"44","author":"Wood","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00107","article-title":"Dramatic response of a PD-L1\u2013positive advanced angiosarcoma of the scalp to pembrolizumab","author":"Hamacher","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.815598","article-title":"Case report: A PD-L1-positive patient with pleomorphic rhabdomyosarcoma achieving an impressive response to immunotherapy","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2026.116590","article-title":"Natural history and treatment sensitivity of alveolar soft part sarcoma: A national multicenter analysis from the French sarcoma group","volume":"237","author":"Kalfala","year":"2026","journal-title":"Eur J Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1871862\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:27:02Z","timestamp":1788496022000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1871862\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":32,"alternative-id":["10.3389\/fonc.2026.1871862"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1871862","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"article-number":"1871862"}}